E I D-Parry
EID Parry reported Q3 FY26 revenue of ₹389 crore, flat YoY, as sugar segment benefited from better realizations (₹40/kg vs ₹37.69) but consumer products declined due to channel restructuring and lower pulse prices.
E I D-Parry vs Biocon Q3 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Biocon
Biocon delivered a solid Q3 FY26 with group revenue of ₹4,173 crore (+9% YoY) and EBITDA of ₹951 crore (+21% YoY), driven by strong biosimilar margins (28% vs 21% last year) and generics growth of 24%.
Result Snapshot
Revenue₹10,316 Cr₹4,173 Cr
PAT₹437 Cr₹-52 Cr
EBITDA Margin8%20%
Sentimentneutralbullish
Key Quotes
We will also announce in Q1 the newer categories we wish to enter in the food FMCG space.
Q3 FY26 represents an important operational inflection point for Biocon. With major capex now largely behind us and operating leverage beginning to play out, we are progressing from a phase of balance sheet resilience into a cycle of sustainable growth, margin expansion and a cash flow-led value creation.